

AGFG2 Polyclonal Antibody

Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP58860

Product Information

Application	WB, IHC-P, IHC-F, IF, E
Primary Accession	O95081
Reactivity	Rat, Pig, Bovine
Host	Rabbit
Clonality	Polyclonal
Calculated MW	48963
Physical State	Liquid
Immunogen	KLH conjugated synthetic peptide derived from human AGFG2
Epitope Specificity	381-481/481
Isotype	IgG
Purity	affinity purified by Protein A
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
SIMILARITY	Contains 1 Arf-GAP domain.
SUBUNIT	Interacts with EPS15R (By similarity).
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	Required for vesicle docking or fusion during acrosome biogenesis (By similarity). May play a role in RNA trafficking or localization. In case of infection by HIV-1, acts as a cofactor for viral Rev and promotes movement of Rev-responsive element-containing RNAs from the nuclear periphery to the cytoplasm. This step is essential for HIV-1 replication.


Additional Information

Gene ID	3268
Other Names	Arf-GAP domain and FG repeat-containing protein 2, HIV-1 Rev-binding protein-like protein, Rev/Rex activation domain-binding protein related, RAB-R, AGFG2, HRBL, RABR
Dilution	WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
Format	0.01M TBS(pH7.4) with 1% BSA, 0.09% (W/V) sodium azide and 50% Glyce
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Protein Information

Name	AGFG2
Synonyms	HRBL, RABR

Images



Sample:
PC-3 Cell (Human) Lysate at 30 ug
Primary: Anti- AGFG2 (AP58860) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 49 kD
Observed band size: 49 kD

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.